Preventing Bleeding in Stem Cell Transplant
Part of Blood & lymphatic clinical trials.
This trial tests if a medication called etamsylate can help prevent bleeding in patients getting a stem cell transplant. If your platelet count drops very low after transplant, this drug may reduce your risk of bleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a blood disease that requires a stem cell transplant.
- Your doctor expects your platelet count to stay very low (10 or lower) for at least 5 days after transplant.
- You have normal blood clotting function, good liver, kidney, and heart function.
- You do not have active bleeding, infection, or a bleeding disorder.
- You are not pregnant or breastfeeding, and you agree to use effective birth control if you can become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether umbilical cord blood can help raise platelet levels in people whose platelets drop after cancer treatment. If it works, it might reduce the need for platelet transfusions and lower bleeding risk.
This study tests a drug called romiplostim to help your body make platelets faster after a stem cell transplant. Platelets help your blood clot, and getting them back sooner can reduce bleeding risks and speed recovery.
This study looks at a new way to predict if patients with blood cancers and very low platelets will have bleeding problems. By doing extra blood tests, researchers hope to create a score that helps doctors prevent bleeds.
This early-phase trial tests a medication to prevent rejection of donated stem cells in children. It's for patients who are at high risk for their transplant to fail.
This trial compares two drugs, romiplostim and rhTPO, to help increase platelet counts after a stem cell transplant in people with MDS or aplastic anemia. The goal is to see which drug works better at reducing the need for platelet transfusions.
This trial tests if romiplostim, a drug that helps the body make platelets, can speed up platelet recovery after a special type of stem cell transplant from a half-matched donor. It may help reduce bleeding risk during the recovery period.
Hear when a new Hematopoietic Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.